NASDAQ:XTLB XTL Biopharmaceuticals Q4 2025 Earnings Report $2.31 +0.11 (+4.77%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast XTL Biopharmaceuticals EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AXTL Biopharmaceuticals Revenue ResultsActual Revenue($0.26) millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AXTL Biopharmaceuticals Announcement DetailsQuarterQ4 2025Date6/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile XTL Biopharmaceuticals Earnings HeadlinesXTL Biopharmaceuticals Ltd. Sponsored ADRJuly 8, 2026 | cnn.comXTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-HoursJuly 1, 2026 | nasdaq.comThe Pentagon Has 120 Days to Solve This Critical Mineral ProblemChina controls roughly 80% of the world's tungsten supply, and new Pentagon sourcing restrictions take effect January 1. The U.S. hasn't mined tungsten domestically since 2015. A little-known Nasdaq company controls Severniy Katpar, one of the largest undeveloped tungsten deposits, with potential to supply 15% of global demand. Two U.S. agencies have floated up to $1.6 billion in financing support as tungsten prices climb as much as 900%.September 24 at 1:00 AM | The Tomorrow Investor (Ad)XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology PlatformJune 30, 2026 | quiverquant.comQXTL Completed the Acquisition of Psyga Bio Ltd.June 30, 2026 | globenewswire.comXTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026June 23, 2026 | tipranks.comSee More XTL Biopharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email. Email Address About XTL BiopharmaceuticalsXTL Biopharmaceuticals (NASDAQ:XTLB) (NASDAQ: XTLB) is an Israel-based clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Its research activities have centered on conditions such as systemic lupus erythematosus and multiple sclerosis, where abnormal immune responses can damage healthy tissue. The company’s development programs have included hCDR1, also known as rigerimod, an immunomodulatory peptide investigated as a potential treatment for systemic lupus erythematosus. XTL has also pursued antibody-based programs, including XTL-6865, as part of its broader effort to develop targeted treatments for autoimmune disorders. XTL Biopharmaceuticals has historically operated as an Israeli biotechnology company whose activities have been directed toward international clinical development and potential global commercialization. The company’s programs remain subject to clinical, regulatory and commercial development requirements, and publicly available information about its current leadership and geographic operations is limited.View XTL Biopharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
